Chronic Lymphocytic Leukemia News and Research

RSS

Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.

Dana-Farber launches clinical test of blood cancer drug in COVID-19 patients

Scientists at Dana-Farber Cancer Institute have launched a clinical test of a blood cancer drug in patients infected with the COVID-19 virus. T

20 May 2020

Drug combo for untreated CLL approved by FDA based on E1912 trial

Patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma now have a new treatment option--a combination of the targeted agent ibrutinib with the immunologic agent rituximab.

29 Apr 2020

Greater occurrence of infections correlates with future cancer diagnosis

Patients experienced a greater occurrence of infections in the years preceding a cancer diagnosis.

17 Apr 2020

New prognostic tool could help improve clinical decision making for leukemia patients

A new prognostic tool predicts how long someone diagnosed with chronic lymphocytic leukemia (CLL) will be able to wait before starting cancer treatment.

8 Apr 2020

New prognostic tool helps leukemia patients plan for cancer treatment

A prognostic tool predicts how long someone diagnosed with chronic lymphocytic leukemia (CLL) can wait before cancer treatment.

8 Apr 2020

Single gene cluster loss promotes initiation and progression of multiple myeloma in mice

The loss of one copy of the miR15a/miR16-1 gene cluster promoted initiation and progression of multiple myeloma in mice.

20 Feb 2020

Universal 'One-Size-Fits-All' Cancer Treatment

Andrew Sewell speaks to News-Medical about his breakthrough research, in which he has discovered a new T-Cell that could treat most cancers.

14 Feb 2020

CD19 CAR NK cell therapy clinical trial shows encouraging results for hematologic cancers

According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia, with no major toxicities observed.

6 Feb 2020

FDA gives clearance to IND application for Calibr's 'switchable' CAR-T cell therapy

Calibr, the drug discovery and development division of Scripps Research, today announced that the U.S. Food and Drug Administration has given clearance to the Investigational New Drug (IND) application for Calibr's "switchable" CAR-T cell therapy, which is being evaluated for the treatment of certain cancers, including relapsed/refractory B-cell malignancies such as non-Hodgkin lymphoma and chronic lymphocytic leukemia.

3 Feb 2020

Researchers reveal mutation's role in blood cancers

A genetic mutation that disrupts how DNA sends messages to the rest of a cell has been linked to a large number of blood cancers.

3 Feb 2020

Study may help develop ibrutinib-based combination therapies for blood cancer

Chronic lymphocytic leukemia (CLL) is the most common form of blood cancer (leukemia) in the Western world, affecting approximately 1.2% of all cancer patients.

30 Jan 2020

OGT launches high-quality NGS panel for research into Chronic Lymphocytic Leukemia

Oxford Gene Technology, A Sysmex Group Company, is excited to announce the launch of its SureSeq CLL + CNV Panel — the company’s latest high-quality, next-generation sequencing offering for research into Chronic Lymphocytic Leukaemia.

From Oxford Gene Technology 16 Jan 2020

Risk of specific genetic translocation is higher in patients of African ancestry, shows study

Multiple myeloma is a plasma cell cancer that is more common in patients of African American descent than of European American descent.

10 Dec 2019

New strategies needed to manage ibrutinib-related toxicities in CLL patients, study suggests

New findings by Yale Cancer Center and Smilow Cancer Hospital researchers show that as the use of the drug ibrutinib climbs in patients with chronic lymphocytic leukemia, so do the rates of patients who stop taking the drug.

9 Dec 2019

Thermo Fisher Scientific to accelerate genomic profiling process in hematology and oncology labs

Clinical researchers who take a traditional sequential approach to analyze myeloid malignancies, a highly heterogeneous group of disorders, face a major hurdle: a laborious and time-consuming workflow.

From Thermo Fisher Scientific Inc. 9 Dec 2019

Ibrutinib-based therapy provides superior clinical outcomes in majority of CLL patients

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) today announced results from an extended follow-up analysis of patients in its randomized Phase 3 clinical trial, E1912.

8 Dec 2019

FDA approves Ohio State-developed drug to treat patients with CLL and SCL

On Nov. 21, 2019, the U.S. Food and Drug Administration approved the use of the drug acalabrutinib for first-line therapy in chronic lymphocytic leukemia and small cell lymphoma.

22 Nov 2019

Cancer drug shows promise in treating metabolic syndrome

Metabolic syndrome is a group of health problems characterized by the presence of elevated blood pressure, increased levels of triglycerides, high blood sugar, excess body fat around the waist, and obesity. If it’s left untreated, it can increase the risk of heart disease, stroke, and type 2 diabetes. Usually, treating metabolic syndrome involves targeting individual risk factors and modifying lifestyle practices.

18 Nov 2019

Rutgers researcher receives $600,000 grant to study chronic lymphocytic leukemia

Rutgers Cancer Institute of New Jersey researcher Hossein Khiabanian, PhD, has received a $600,000 Translational Award from the V Foundation for Cancer Research to study chronic lymphocytic leukemia with the aim of developing research models that may help investigators better understand how CLL cells are influenced by new therapies.

11 Nov 2019

MD Anderson and Takeda announce agreement to develop off-the-shelf CAR NK-cell therapy platform

The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited today announced an exclusive license agreement and research agreement to develop cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies, 'armored' with IL-15, for the treatment of B-cell malignancies and other cancers.

5 Nov 2019